Biologic Agents for Inflammatory Bowel Disease (The Current, the Future and the Controversy)

摘要: Inflammatory bowel conditions (IBD) are chronic relapsing diseases. Crohn’s disease (CD) is characterised by transmural inflammation due to an imbalance between proand antiinflammatory molecules. Ulcerative colitis (UC) only a mucosal disease, however one quarter of patients develop fulminating and 20% require surgery. Treatment objectives usually include steroid-free remission, decrease in hospitalization surgery sustained clinical remission healing as well reduction the risk dysplasia cancer. The description cell signalling cascade over past 20 years has led surge potential treatments for IBD. It was initially thought that since CD mediated through T helper 1 cascade, using specific molecules block it would be reasonable approach cure. A multitude medications trials later proved this theory true. In addition, UC which different inflammatory (T 2) soon discovered respond these newer fact several showed cells prevalent serum, stool mucosa with active UC. better knowledge pathways IBD lead development new targeted therapies actions including inhibition leukocytes trafficking, activation or polarization proinflammatory cytokines. Additionally technique called humanization developed advances protein engineering production partially humanized finally fully antibodies.